PTIX

Protagenic Therapeutics, Inc. [PTIX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PTIX Stock Summary

In the News

PTIX Financial details

Company Rating
-
Market Cap
6.39M
Income
-5.01M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-0.95
Forward P/E
-
PEG
-0.25
P/S
-
P/B
0.9
P/C
-
P/FCF
-1.39
Quick Ratio
4.12
Current Ratio
4.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
38.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
18.75%
-
-
-
-
SMA20
-
SMA50
-25%
SMA100
-57.81%
Inst Own
-
Inst Trans
-
ROA
-73%
ROE
-69%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.68-2.32
52W High
-
52W Low
-
RSI
41.18
Rel Volume
25.72
Avg Volume
10.43K
Volume
268.19K
Perf Week
-21.72%
Perf Month
-35.13%
Perf Quarter
-67.36%
Perf Half Y
-70.14%
-
-
-
-
Beta
0.383
-
-
Volatility
0.03%, 0.04%
Prev Close
-12.88%
Price
0.209
Change
-16.96%

Something similar

Top by Market Cap
EMBASSY.NS
AMZ.DE
VTSAX
LLY.DE
META
Same Sector
HCYT
UTMD
PARD3.SA
POLN.SW
004720.KS
Same Price Range
ECU.V
1181.HK
0IH3.L
BLDEW
1870.HK
Similar Market Cap
AMCA
USDR
PRM.MI
BNOX
USOD

Company Profile

Healthcare Biotechnology
  • Volume Average 10.43K
  • Market Capitalization 6.39M
  • Employee 1
  • CEO Dr. Garo H. Armen Ph.D.
  • Headquarters New York,NY,US
  • IPO Date 2021-04-27
  • Website https://www.protagenic.com

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.